← 返回前沿论文

压力升高 A549 肺腺癌细胞中 PD-L1 表达并导致对抗 ROR1 CAR T 细胞介导细胞毒性的耐药

英文原题:Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity.

PubMed 2022/04/28(内容时间) Sci Rep Q1 · IF 4.9(JCR 2025)

研究概要

我们的研究表明,肿瘤微环境中的压力升高可能通过上调 PD-L1 表达来削弱 T 细胞疗法,而将 CAR T 疗法与免疫检查点抑制剂联合使用可以克服这一问题。

中文摘要

由于异常的血管生成和增殖,肿瘤微环境处于缺氧、缺乏营养和高间质压力的状态。与氧气和营养相比,压力对癌症生物学的影响研究仍然较少。在此,我们构建了ROR1-CAR T细胞,并与在有无升高压力条件下培养的A549细胞共培养。随后我们通过流式细胞术和荧光素酶活性检测了细胞凋亡和细胞死亡。我们还通过ELISA检测了细胞因子(IL-2、IFN-和TNF-)的释放。结果表明,压力预处理的A549细胞对ROR1-CAR T细胞介导的细胞毒性具有更强的抵抗性。压力预处理似乎不影响ROR1-CAR的表达或细胞因子的产生。然而,压力预处理上调了A549细胞中PD-L1的表达,并减少了ROR1-CAR T细胞的细胞因子释放。此外,阻断PD-1::PD-L1相互作用的Pembrolizumab和Cemiplimab增加了ROR1-CAR T细胞的细胞因子产生,增加了A549细胞的凋亡性细胞死亡,并改善了ROR1-CAR T介导的细胞毒性。在异种移植小鼠中,压力预处理增加了A549细胞的致瘤性,而使用Pembrolizumab和ROR1-CAR T细胞的联合治疗可以阻断这一效应。总之,我们的研究表明,肿瘤微环境中升高的压力可能通过上调PD-L1表达来削弱T细胞疗法的效果,而将CAR T疗法与免疫检查点抑制剂联合使用可以克服这一问题。

展开英文摘要原文

Due to the abnormal vasculation and proliferation, the tumor microenvironment is hypoxic, lacking nutrients, and under high interstitial pressure. Compared to oxygen and nutrients, the effect of pressure on cancer biology remains poorly studied. Here we constructed ROR1-CAR T cells and co-cultured with A549 cells with and without elevated pressure. We then measured apoptosis and cell death by flow cytometry and luciferase activity. We also measured cytokine (IL-2, IFN- , and TNF- ) release by ELISA. The results show that pressure-preconditioned A549 cells are much resistant to ROR1-CAR T cell-mediated cytotoxicity. Pressure preconditioning does not appear to affect the expression of ROR1-CAR or cytokine production. However, pressure preconditioning upregulates PD-L1 expression in A549 cells and decreases cytokine release from ROR1-CAR T cells. In addition, Pembrolizumab and Cemiplimab that block PD-1::PD-L1 interaction increase the cytokine production in ROR1-CAR T cells, increase the apoptotic cell death in A549 cells, and improve the ROR1-CAR T-mediated cytotoxicity. In xenograft mice, pressure preconditioning increases tumorigenesis of A549 cells, which can be blocked by a combined therapy using Pembrolizumab and ROR1-CAR T cells. Together, our studies suggest that elevated pressure in the tumor microenvironment could blunt the T cell therapy by upregulating PD-L1 expression, which could be overcome by combining CAR T therapy with immune checkpoint inhibitors.

论文信息

作者
Ou Z、Dou X、Tang N、Liu G
第一作者单位
Department of General Surgery, Xiangya Hospital Central South University, Xiangya Road 87#, Changsha, 410008, Hunan, China.China
通讯作者单位
Department of General Surgery, Xiangya Hospital Central South University, Xiangya Road 87#, Changsha, 410008, Hunan, China. guodongliu@csu.edu.cn.China
期刊
Scientific reports2022 Apr 28
原文标识
PubMed 35484298 · DOI 10.1038/s41598-022-10905-6